Clinicopathological patient characteristics of the gastric cancer cohort and correlation with RHOA genotype
| Characteristic | Valid (n) | Total | RHOA wildtype (n (%)) | RHOA mutation (n (%)) | p Value | |
|---|---|---|---|---|---|---|
| Gender | 415 | Female | 166 (40.0) | 157 (94.6) | 9 (5.4) | 0.199* |
| Male | 249 (60.0) | 242 (97.2) | 7 (2.8) | |||
| Age | 402 | ≤68 years | 198 (49.3) | 190 (96.0) | 8 (4.0) | 1.000* |
| >68 years | 204 (50.7) | 196 (96.1) | 8 (3.9) | |||
| Laurén phenotype | 415 | Intestinal | 210 (50.6) | 206 (98.1) | 4 (1.9) | 0.110* |
| Diffuse | 134 (32.3) | 125 (93.3) | 9 (6.7) | |||
| Mixed | 27 (6.5) | 27 (96.4) | 1 (3.6) | |||
| Unclassified | 41 (9.9) | 41 (95.3) | 2 (4.7) | |||
| Mucin phenotype | 365 | Intestinal | 102 (27.9) | 99 (97.1) | 3 (2.9) | 0.753* |
| Gastric | 57 (15.6) | 55 (96.5) | 2 (3.5) | |||
| Mixed | 146 (37.3) | 139 (95.2) | 7 (4.8) | |||
| Unclassified | 60 (16.4) | 59 (98.3) | 1 (1.7) | |||
| Localisation | 415 | Proximal | 127 (30.6) | 124 (97.6) | 3 (2.4) | 0.410* |
| Distal | 288 (69.4) | 275 (95.5) | 13 (4.5) | |||
| T-category | 415 | T1a/b | 47 (11.3) | 44 (93.6) | 3 (6.4) | 0.086† |
| T2 | 49 (11.8) | 46 (93.9) | 3 (6.1) | |||
| T3 | 169 (40.7) | 162 (95.9) | 7 (4.1) | |||
| T4a/b | 150 (36.1) | 147 (98.0) | 3 (2.0) | |||
| T-category (grouped) | 415 | T1/T2 | 96 (22.6) | 90 (93.8) | 6 (6.2) | 0.221* |
| T3/T4 | 319 (77.4) | 309 (96.9) | 10 (3.1) | |||
| N-category | 413 | N0 | 116 (28.1) | 111 (95.7) | 5 (4.3) | 0.786† |
| N1 | 58 (14.0) | 56 (96.6) | 2 (3.4) | |||
| N2 | 69 (16.7) | 66 (95.7) | 3 (4.3) | |||
| N3/a/b | 170 (41.2) | 164 (96.5) | 6 (3.5) | |||
| L-category | 403 | L0 | 186 (46.2) | 178 (95.7) | 8 (4.3) | 0.802* |
| L1 | 217 (53.8) | 209 (96.3) | 8 (3.7) | |||
| M-category | 415 | M0 | 343 (82.7) | 327 (95.3) | 16 (4.7) | 0.086* |
| M1 | 72 (17.3) | 72 (100) | 0 (0) | |||
| V-category | 402 | V0 | 353 (87.8) | 339 (96.0) | 14 (4.0) | 1.000* |
| V1 | 49 (12.2) | 47 (95.9) | 2 (4.1) | |||
| Stage (7th edn) | 407 | IA | 35 (8.6) | 33 (94.3) | 2 (5.7) | 0.127† |
| IB | 29 (7.1) | 27 (93.1) | 2 (6.9) | |||
| IIA | 52 (12.8) | 51 (98.1) | 1 (1.9) | |||
| IIB | 43 (10.6) | 41 (95.3) | 2 (4.7) | |||
| IIIA | 46 (11.3) | 42 (91.3) | 4 (8.7) | |||
| IIIB | 70 (17.2) | 67 (95.7) | 3 (4.3) | |||
| IIIC | 60 (14.7) | 58 (96.7) | 2 (3.3) | |||
| IV | 72 (17.7) | 72 (100) | 0 (0) | |||
| LNR (median=0.214) | 407 | ≤0.214 | 204 (50.1) | 197 (96.6) | 7 (3.4) | 0.622* |
| >0.214 | 203 (49.9) | 194 (95.6) | 9 (4.4) | |||
| Tumour grade | 405 | G1/G2 | 91 (22.5) | 90 (98.9) | 1 (1.1) | 0.136* |
| G3/G4 | 314 (77.5) | 299 (95.2) | 15 (4.8) | |||
| Resection margin | 394 | R0 | 346 (87.8) | 335 (96.8) | 11 (3.2) | 0.664* |
| R1/R2 | 48 (12.2) | 46 (95.8) | 2 (4.2) | |||
| E-Cadherin‡ | 382 | Negative | 280 (73.3) | 268 (95.7) | 12 (4.3) | 0.768* |
| Positive | 102 (26.7) | 99 (97.1) | 3 (2.9) | |||
| β-Catenin‡ | 384 | Negative | 213 (55.5) | 202 (94.8) | 11 (5.2) | 0.191* |
| Positive | 171 (44.5) | 167 (97.7) | 4 (2.3) | |||
| Lysozyme‡ | 384 | Negative | 182 (47.4) | 179 (98.4) | 3 (1.6) | 0.035* |
| Positive | 202 (52.6) | 190 (94.1) | 12 (5.9) | |||
| Survival (months) | 402 | Events (Dead) | 318 (79.1) | 305 (95.9) | 13 (4.1) | 0.457§ |
| Alive | 84 (20.9) | 81 (96.4) | 3 (3.6) | |||
| Median survival | 14.6±1.1 | 11.6±2.4 | ||||
| 95% CI | 12.4 to 16.8 | 6.9 to 16.4 |
*Fisher's exact test.
†Kendall’s tau test.
‡Dichotomized at the median.
§Log-rank test.